



ATRIO Health Plans

2021 Step Therapy Requirements PPO Plans

**Effective: 1/1/2021
Last Updated: 10/5/2020**

AMLODIPINE ORAL SUSPENSION

Products Affected

Step 2:

- KATERZIA 1 MG/ML ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR GENERIC AMLODIPINE TABLETS WITHIN THE PAST 120 DAYS.
-----------------	--

ANTIBACTERIALS (EENT)

Products Affected

Step 2:

- BESIVANCE 0.6 % EYE
DROPS,SUSPENSION

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF CIPROFLOXACIN OPHTHALMIC OR OFLOXACIN OPHTHALMIC DROPS WITHIN THE LAST 120 DAYS.
-----------------	---

ANTIDEPRESSANTS

Products Affected

Step 2:

- FETZIMA 120 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK
- FETZIMA 20 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG CAPSULE,EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR TRINTELLIX AND VIIBRYD WITHIN THE PAST 365 DAYS.
----------	--

ANTIPSYCHOTIC AGENTS

Products Affected

Step 2:

- *aripiprazole 10 mg disintegrating tablet*
- *aripiprazole 15 mg disintegrating tablet*
- CAPLYTA 42 MG CAPSULE
- *clozapine 100 mg disintegrating tablet*
- *clozapine 12.5 mg disintegrating tablet*
- *clozapine 150 mg disintegrating tablet*
- *clozapine 200 mg disintegrating tablet*
- *clozapine 25 mg disintegrating tablet*
- FANAPT 1 MG TABLET
- FANAPT 10 MG TABLET
- FANAPT 12 MG TABLET
- FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK
- FANAPT 2 MG TABLET
- FANAPT 4 MG TABLET
- FANAPT 6 MG TABLET
- FANAPT 8 MG TABLET
- SAPHRIS 10 MG SUBLINGUAL TABLET
- SAPHRIS 2.5 MG SUBLINGUAL TABLET
- SAPHRIS 5 MG SUBLINGUAL TABLET
- SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- VERSACLOZ 50 MG/ML ORAL SUSPENSION
- VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK
- VRAYLAR 1.5 MG CAPSULE
- VRAYLAR 3 MG CAPSULE
- VRAYLAR 4.5 MG CAPSULE
- VRAYLAR 6 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR LATUDA AND ONE FORMULARY ORAL ANTIPSYCHOTIC: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE WITHIN THE PAST 365 DAYS
-----------------	---

ANTIPSYCHOTIC AGENTS II

Products Affected

Step 2:

- REXULTI 0.25 MG TABLET
- REXULTI 0.5 MG TABLET
- REXULTI 1 MG TABLET
- REXULTI 2 MG TABLET
- REXULTI 3 MG TABLET
- REXULTI 4 MG TABLET

Details

Criteria	PRIOR CLAIM FOR LATUDA AND ONE FORMULARY ORAL ATYPICAL ANTIPSYCHOTICS (RISPERIDONE, CLOZAPINE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE OR ZIPRASIDONE) OR SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE) OR SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE) WITHIN THE PAST 365 DAYS
----------	---

ANTIULCER AGENTS

Products Affected

Step 2:

- DEXILANT 30 MG CAPSULE, DELAYED RELEASE *gram capsule*
- DEXILANT 60 MG CAPSULE, DELAYED RELEASE *omeprazole 40 mg-sodium bicarbonate 1.1 gram capsule*
- *omeprazole 20 mg-sodium bicarbonate 1.1* *rabeprazole 20 mg tablet, delayed release*

Details

Criteria	PRIOR CLAIM FOR GENERIC FEDERAL LEGEND FORMULARY VERSION OF ORAL LANSOPRAZOLE CAPSULES, OMEPRAZOLE, OR PANTOPRAZOLE WITHIN THE PAST 120 DAYS.
-----------------	---

B VERSUS D ADMINISTRATIVE STEP

Products Affected

Step 2:

- CYCLOPHOSPHAMIDE 25 MG CAPSULE
- CYCLOPHOSPHAMIDE 50 MG CAPSULE
- *methotrexate sodium 2.5 mg tablet*
- XATMEP 2.5 MG/ML ORAL SOLUTION

Details

Criteria	IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG.
----------	--

DENOSUMAB

Products Affected

Step 2:

- PROLIA 60 MG/ML SUBCUTANEOUS SYRINGE

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF ALENDRONATE, IBANDRONATE OR RISEDRONATE WITHIN THE PAST 120 DAYS. PROLIA REQUIRES A STEP THERAPY EXCEPTION REQUEST FOR MEMBERS WITH A DIAGNOSIS OF PROSTATE CANCER AND USED FOR BONE LOSS IN MEN OR DIAGNOSIS OF BREAST CANCER AND USED TO INCREASE BONE MASS IN WOMEN AT HIGH RISK OF FRACTURES RECEIVING AROMATASE INHIBITOR THERAPY
-----------------	---

DPP-4 INHIBITORS

Products Affected

Step 2:

- JENTADUETO 2.5 MG-1,000 MG TABLET
- JENTADUETO 2.5 MG-500 MG TABLET
- JENTADUETO 2.5 MG-850 MG TABLET
- JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE
- TRADJENTA 5 MG TABLET

Details

Criteria	PRIOR CLAIM FOR JANUMET, JANUMET XR OR JANUVIA WITHIN THE PAST 120 DAYS
----------	---

DULOXETINE SPRINKLE

Products Affected

Step 2:

- DRIZALMA SPRINKLE 20 MG CAPSULE, DELAYED RELEASE
- DRIZALMA SPRINKLE 30 MG CAPSULE, DELAYED RELEASE
- DRIZALMA SPRINKLE 40 MG CAPSULE, DELAYED RELEASE
- DRIZALMA SPRINKLE 60 MG CAPSULE, DELAYED RELEASE

Details

Criteria	PRIOR CLAIM FOR FORMULARY GENERIC DULOXETINE CAPSULE WITHIN THE PAST 120 DAYS.
-----------------	--

ELUXADOLINE

Products Affected

Step 2:

- VIBERZI 100 MG TABLET
- VIBERZI 75 MG TABLET

Details

Criteria	PRIOR CLAIM FOR DICYCLOMINE WITHIN THE PAST 120 DAYS.
-----------------	---

ENALAPRIL ORAL SOLUTION

Products Affected

Step 2:

- EPANED 1 MG/ML ORAL SOLUTION

Details

Criteria	PRIOR CLAIM FOR GENERIC ENALAPRIL ORAL WITHIN THE PAST 120 DAYS.
-----------------	--

GABAPENTIN SR

Products Affected

Step 2:

- GRALISE 300 MG TABLET,EXTENDED RELEASE
- GRALISE 30-DAY STARTER PACK 300 MG (9)-600 MG (69) TABLET,EXT.
- GRALISE 600 MG TABLET,EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR GABAPENTIN IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
----------	--

LESINURAD

Products Affected

Step 2:

- *febuxostat 40 mg tablet*
- *febuxostat 80 mg tablet*

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF ALLOPURINOL TABLETS WITHIN THE PAST 120 DAYS.
-----------------	--

LISINOPRIL ORAL SOLUTION

Products Affected

Step 2:

- QBRELIS 1 MG/ML ORAL SOLUTION

Details

Criteria	PRIOR CLAIM FOR GENERIC LISINOPRIL WITHIN THE PAST 120 DAYS.
-----------------	--

MEMANTINE - DONEPEZIL

Products Affected

Step 2:

- NAMZARIC 14 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE
- NAMZARIC 21 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE
- NAMZARIC 28 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE
- NAMZARIC 7 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE
- NAMZARIC 7/14/21/28 MG-10 MG CAPSULE,SPRINKLE,EXTEND RELEASE,DOSE PACK

Details

Criteria	PRIOR CLAIM FOR GENERIC DONEPEZIL AND MEMANTINE IR IN THE PAST 365 DAYS
----------	---

NASAL CORTICOSTEROIDS II

Products Affected

Step 2:

- XHANCE 93 MCG/ACTUATION
BREATH ACTIVATED AEROSOL

Details

Criteria	PRIOR CLAIM FOR A FEDERAL LEGEND FORMULARY VERSION OF MOMETASONE NASAL SPRAY WITHIN THE PAST 120 DAYS
-----------------	---

NOVEL ORAL ANTICOAGULANTS

Products Affected

Step 2:

- PRADAXA 110 MG CAPSULE
- PRADAXA 150 MG CAPSULE
- PRADAXA 75 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR ELIQUIS AND XARELTO IN THE PAST 365 DAYS.
-----------------	---

OPHTHALMIC ALLERGY - OTC

Products Affected

Step 2:

- ALREX 0.2 % EYE DROPS,SUSPENSION
- BEPREVE 1.5 % EYE DROPS

Details

Criteria	PRIOR CLAIM FOR ONE OF THE FOLLOWING: OTC LORATADINE, OTC LORATADINE D, OTC CETIRIZINE, OTC CETIRIZINE D, OTC FEXOFENADINE, OTC FEXOFENADINE D, OTC LEVOCETIRIZINE, OTC GENERIC KETOTIFEN EYE DROPS 0.025%, LEVOCETIRIZINE, CROMOLYN SODIUM, EPINASTINE, OR FORMULARY OLOPATADINE EYE DROPS WITHIN THE PAST 120 DAYS.
-----------------	---

OPHTHALMIC PROSTAGLANDINS

Products Affected

Step 2:

- XELPROS 0.005 % EYE DROP
EMULSION

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF LATANOPROST (GENERIC XALATAN OR XALATAN) OR TRAVOPROST AND ONE OF: ALPHAGAN P 0.1%, AZOPT, COMBIGAN, LUMIGAN 0.01%, SIMBRINZA, OR ROCKLATAN WITHIN THE PAST 365 DAYS.
-----------------	--

ROSUVASTATIN SPRINKLE

Products Affected

Step 2:

- EZALLOR SPRINKLE 10 MG CAPSULE
- EZALLOR SPRINKLE 20 MG CAPSULE
- EZALLOR SPRINKLE 40 MG CAPSULE
- EZALLOR SPRINKLE 5 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR GENERIC ROSUVASTATIN TABLET IN THE PAST 120 DAYS.
-----------------	---

SELEGILINE PATCH

Products Affected

Step 2:

- EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- TRANSDERMAL 24 HOUR PATCH • EMSAM 9 MG/24 HR
- EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH

Details

Criteria	ST Criteria: Pending CMS Approval
-----------------	-----------------------------------

SPIRONOLACTONE ORAL SUSPENSION

Products Affected

Step 2:

- CAROSPIR 25 MG/5 ML ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR GENERIC SPIRONOLACTONE WITHIN THE PAST 120 DAYS.
-----------------	--

INDEX

ALREX 0.2 % EYE DROPS,SUSPENSION.....	19	EZALLOR SPRINKLE 40 MG CAPSULE.....	21
<i>aripiprazole 10 mg disintegrating tablet</i>	4	EZALLOR SPRINKLE 5 MG CAPSULE.....	21
<i>aripiprazole 15 mg disintegrating tablet</i>	4	FANAPT 1 MG TABLET.....	4
BEPREVE 1.5 % EYE DROPS.....	19	FANAPT 10 MG TABLET.....	4
BESIVANCE 0.6 % EYE DROPS,SUSPENSION.....	2	FANAPT 12 MG TABLET.....	4
CAPLYTA 42 MG CAPSULE.....	4	FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK.....	4
CAROSPIR 25 MG/5 ML ORAL SUSPENSION.....	23	FANAPT 2 MG TABLET.....	4
<i>clozapine 100 mg disintegrating tablet</i>	4	FANAPT 4 MG TABLET.....	4
<i>clozapine 12.5 mg disintegrating tablet</i>	4	FANAPT 6 MG TABLET.....	4
<i>clozapine 150 mg disintegrating tablet</i>	4	FANAPT 8 MG TABLET.....	4
<i>clozapine 200 mg disintegrating tablet</i>	4	<i>febuxostat 40 mg tablet</i>	14
<i>clozapine 25 mg disintegrating tablet</i>	4	<i>febuxostat 80 mg tablet</i>	14
CYCLOPHOSPHAMIDE 25 MG CAPSULE.....	7	FETZIMA 120 MG CAPSULE,EXTENDED RELEASE.....	3
CYCLOPHOSPHAMIDE 50 MG CAPSULE.....	7	FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK.....	3
DEXILANT 30 MG CAPSULE, DELAYED RELEASE.....	6	FETZIMA 20 MG CAPSULE,EXTENDED RELEASE.....	3
DEXILANT 60 MG CAPSULE, DELAYED RELEASE.....	6	FETZIMA 40 MG CAPSULE,EXTENDED RELEASE.....	3
DRIZALMA SPRINKLE 20 MG CAPSULE,DELAYED RELEASE.....	10	FETZIMA 80 MG CAPSULE,EXTENDED RELEASE.....	3
DRIZALMA SPRINKLE 30 MG CAPSULE,DELAYED RELEASE.....	10	GRALISE 300 MG TABLET,EXTENDED RELEASE.....	13
DRIZALMA SPRINKLE 40 MG CAPSULE,DELAYED RELEASE.....	10	GRALISE 30-DAY STARTER PACK 300 MG (9)-600 MG (69) TABLET,EXT. RELEASE.....	13
DRIZALMA SPRINKLE 60 MG CAPSULE,DELAYED RELEASE.....	10	GRALISE 600 MG TABLET,EXTENDED RELEASE.....	13
EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH...22		JENTADUETO 2.5 MG-1,000 MG TABLET.....	9
EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH...22		JENTADUETO 2.5 MG-500 MG TABLET.....	9
EMSAM 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH...22		JENTADUETO 2.5 MG-850 MG TABLET.....	9
EPANED 1 MG/ML ORAL SOLUTION.....	12	JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE.....	9
EZALLOR SPRINKLE 10 MG CAPSULE.....	21	JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE.....	9
EZALLOR SPRINKLE 20 MG CAPSULE.....	21		

KATERZIA 1 MG/ML ORAL SUSPENSION.....	1	SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH....	4
<i>methotrexate sodium 2.5 mg tablet</i>	7	TRADJENTA 5 MG TABLET.....	9
NAMZARIC 14 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE.....	16	VERSACLOZ 50 MG/ML ORAL SUSPENSION.....	4
NAMZARIC 21 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE.....	16	VIBERZI 100 MG TABLET.....	11
NAMZARIC 28 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE.....	16	VIBERZI 75 MG TABLET.....	11
NAMZARIC 7 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE....	16	VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK.....	4
NAMZARIC 7/14/21/28 MG-10 MG CAPSULE,SPRINKLE,EXTEND RELEASE,DOSE PACK.....	16	VRAYLAR 1.5 MG CAPSULE.....	4
<i>omeprazole 20 mg-sodium bicarbonate 1.1 gram capsule</i>	6	VRAYLAR 3 MG CAPSULE.....	4
<i>omeprazole 40 mg-sodium bicarbonate 1.1 gram capsule</i>	6	VRAYLAR 4.5 MG CAPSULE.....	4
PRADAXA 110 MG CAPSULE.....	18	VRAYLAR 6 MG CAPSULE.....	4
PRADAXA 150 MG CAPSULE.....	18	XATMEP 2.5 MG/ML ORAL SOLUTION.....	7
PRADAXA 75 MG CAPSULE.....	18	XELPROS 0.005 % EYE DROP EMULSION.....	20
PROLIA 60 MG/ML SUBCUTANEOUS SYRINGE.....	8	XHANCE 93 MCG/ACTUATION BREATH ACTIVATED AEROSOL.....	17
QBRELIS 1 MG/ML ORAL SOLUTION.....	15		
<i>rabeprazole 20 mg tablet, delayed release</i>	6		
REXULTI 0.25 MG TABLET.....	5		
REXULTI 0.5 MG TABLET.....	5		
REXULTI 1 MG TABLET.....	5		
REXULTI 2 MG TABLET.....	5		
REXULTI 3 MG TABLET.....	5		
REXULTI 4 MG TABLET.....	5		
SAPHRIS 10 MG SUBLINGUAL TABLET.....	4		
SAPHRIS 2.5 MG SUBLINGUAL TABLET.....	4		
SAPHRIS 5 MG SUBLINGUAL TABLET.....	4		
SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH....	4		
SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH....	4		